The European Commission has approved a new 7.2 mg once‑weekly maintenance dose of Wegovy (semaglutide injection) for adults living with obesity. This gives doctors another option to help… read more.
Eli Lilly and Company announced that access to self-pay pricing on the new Zepbound (tirzepatide) KwikPen for single-patient use will be available at LillyDirect and major pharmacies nationwide,… read more.
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ‘eye stroke’ (ischaemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an… read more.
A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain on average 60% of their lost weight – but beyond this, their weight… read more.
Glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity may also help to lower the risk of addiction to a range of substances including… read more.
Eli Lilly and Company announced the FDA approved a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen that delivers a full month of treatment… read more.
An international research group has examined how many people are affected by preclinical and clinical obesity and what health risks are associated with this. The team led by… read more.
The EMA’s CHMP adopted a positive opinion, recommending the granting of a conditional marketing authorisation for Kayshild (semaglutide), intended for the treatment of adults with non-cirrhotic metabolic dysfunction-associated… read more.
A new study from Adelaide University is turning a spotlight on those tablet versions, finding that the absorption-enhancing ingredient salcaprozate sodium (SNAC) may have measurable adverse biological effects for the gut and… read more.
Researchers from a large international study report that obesity significantly increases the risk of hospitalization and death from many infectious diseases, including flu, COVID-19, pneumonia, gastroenteritis, urinary tract… read more.
Novo Nordisk announced that the FDA has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and… read more.
An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
